

# Brent A Neuschwander-Tetri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6472896/publications.pdf>

Version: 2024-02-01

84  
papers

17,680  
citations

43973

48  
h-index

54797

84  
g-index

89  
all docs

89  
docs citations

89  
times ranked

16630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Two Faces of Pioglitazone: Sorting Out the Roles of its PPAR $\alpha$ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple. <i>Hepatology Communications</i> , 2022, 6, 3003-3005.	2.0	1
2	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2022, 76, 506-517.	1.8	49
3	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	1.8	74
4	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.3	7
5	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	1.9	9
6	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	9.4	68
7	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.	3.6	86
8	Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease. <i>Digestive Diseases</i> , 2021, 39, 247-257.	0.8	11
9	coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. <i>Hepatology Communications</i> , 2021, 5, 774-785.	2.0	3
10	The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Contemporary Clinical Trials</i> , 2021, 104, 106335.	0.8	38
11	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	0.6	101
12	The Importance of Glycemic Equipoise in NASH. <i>Hepatology</i> , 2021, 74, 1145-1147.	3.6	2
13	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. <i>New England Journal of Medicine</i> , 2021, 385, 1559-1569.	13.9	406
14	Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. <i>Molecular Metabolism</i> , 2021, 54, 101364.	3.0	9
15	Too Much Sugarâ€”The Notâ€”Sweet Reality of Its Impact on Our Health. <i>Hepatology</i> , 2020, 71, 377-379.	3.6	3
16	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	0.8	92
17	The molecular basis for current targets of NASH therapies. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 151-161.	1.9	15
18	The metabolic basis of nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00112.	1.0	64

#	ARTICLE	IF	CITATIONS
19	Therapeutic Landscape for NAFLD in 2020. <i>Gastroenterology</i> , 2020, 158, 1984-1998.e3.	0.6	136
20	Multicenter Validation of Association Between Decline in MRIâ€PDFF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	3.6	79
21	Inappropriate Testing for Acute Viral Hepatitis Is Commonâ€”Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States. <i>Ochsner Journal</i> , 2020, 20, 293-298.	0.5	0
22	Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. <i>Hepatology</i> , 2019, 70, 522-531.	3.6	106
23	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2019, 394, 2012-2024.	6.3	401
24	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2019, 2, e1912565.	2.8	230
25	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019, 70, 1841-1855.	3.6	64
26	Correlates, Trends, and Short-Term Outcomes of Venous Thromboembolism in Hospitalized Patients with Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 357-360.	0.6	2
27	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1877-1885.e5.	2.4	145
28	Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network. <i>Radiology: Artificial Intelligence</i> , 2019, 1, 180022.	3.0	78
29	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.2	65
30	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	2.4	322
31	An Inhibitor of Arginineâ€Glycineâ€Aspartateâ€Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2019, 3, 246-261.	2.0	28
32	Pegbelfermin (BMSâ€986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. <i>Obesity</i> , 2019, 27, 41-49.	1.5	180
33	Relationship between three commonly used nonâ€invasive fibrosis biomarkers and improvement in fibrosis stage in patients with nonâ€alcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 924-932.	1.9	47
34	Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1511-1520.e5.	2.4	111
35	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125
36	Performance characteristics of vibrationâ€controlled transient elastography for evaluation of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2018, 67, 134-144.	3.6	192

#	ARTICLE	IF	CITATIONS
37	Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>Lancet, The</i> , 2018, 392, 2705-2717.	6.3	374
38	Mechanisms of NAFLD development and therapeutic strategies. <i>Nature Medicine</i> , 2018, 24, 908-922.	15.2	2,392
39	Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. <i>Hepatology</i> , 2017, 65, 1088-1090.	3.6	20
40	Non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2017, 15, 45.	2.3	339
41	Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 968-978.	1.1	53
42	Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017, 153, 753-761.	0.6	209
43	Brown adipose tissue detected by PET/CT imaging is associated with less central obesity. <i>Nuclear Medicine Communications</i> , 2017, 38, 629-635.	0.5	31
44	Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. <i>Contemporary Clinical Trials</i> , 2017, 61, 33-38.	0.8	38
45	New insights into the role of Lith genes in the formation of cholesterol-supersaturated bile. <i>Liver Research</i> , 2017, 1, 42-53.	0.5	16
46	Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. <i>Gastroenterology</i> , 2017, 153, 621-625.e7.	0.6	24
47	Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 198-207.	1.3	22
48	Future Treatments of NASH. <i>Current Hepatology Reports</i> , 2016, 15, 125-133.	0.4	2
49	In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. <i>Gastroenterology</i> , 2016, 151, 1141-1154.e9.	0.6	100
50	Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 499-518.	2.3	25
51	End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 11-13.	0.6	19
52	Practice patterns in NAFLD and NASH: real life differs from published guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 4-12.	1.4	72
53	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15080.	18.1	612
54	The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. <i>Molecular Metabolism</i> , 2015, 4, 353-357.	3.0	64

#	ARTICLE	IF	CITATIONS
55	Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. <i>Diabetes Care</i> , 2015, 38, 1347-1355.	4.3	162
56	Targeting the FXR Nuclear Receptor to Treat Liver Disease. <i>Gastroenterology</i> , 2015, 148, 704-706.	0.6	18
57	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2015, 385, 956-965.	6.3	1,840
58	Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2121-2130.e2.	2.4	97
59	Differences in the Degree of Cerulein-Induced Chronic Pancreatitis in C57BL/6 Mouse Substrains Lead to New Insights in Identification of Potential Risk Factors in the Development of Chronic Pancreatitis. <i>American Journal of Pathology</i> , 2013, 183, 692-708.	1.9	58
60	Carbohydrate intake and nonalcoholic fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2013, 16, 446-452.	1.3	70
61	Dietary <i>trans</i> -Fatty Acid Induced NASH is Normalized Following Loss of <i>trans</i> -Fatty Acids from Hepatic Lipid Pools. <i>Lipids</i> , 2012, 47, 941-950.	0.7	48
62	Farnesoid X Receptor Agonists: What They Are and How They Might Be Used in Treating Liver Disease. <i>Current Gastroenterology Reports</i> , 2012, 14, 55-62.	1.1	16
63	Reply:. <i>Hepatology</i> , 2011, 53, 1405-1405.	3.6	6
64	Nontriglyceride Hepatic Lipotoxicity: The New Paradigm for the Pathogenesis of NASH. <i>Current Gastroenterology Reports</i> , 2010, 12, 49-56.	1.1	56
65	Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. <i>Hepatology</i> , 2010, 52, 774-788.	3.6	850
66	Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 913-924.	3.6	397
67	Angiotensin II signaling through the AT1a and AT1b receptors does not have a role in the development of cerulein-induced chronic pancreatitis in the mouse. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G70-G80.	1.6	18
68	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2010, 362, 1675-1685.	13.9	2,718
69	Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G284-G294.	1.6	39
70	Reply:. <i>Hepatology</i> , 2009, 49, 2127-2128.	3.6	0
71	Reply:. <i>Hepatology</i> , 2009, 50, 321-322.	3.6	0
72	Lifestyle Modification as the Primary Treatment of NASH. <i>Clinics in Liver Disease</i> , 2009, 13, 649-665.	1.0	58

#	ARTICLE	IF	CITATIONS
73	Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction. <i>Gastroenterology</i> , 2007, 133, 80-90.	0.6	425
74	Food energy efficiency, cannabinoids, and a slow death of the weight loss dogma. <i>Hepatology</i> , 2007, 46, 12-15.	3.6	7
75	Induced thrombospondin expression in the mouse pancreas during pancreatic injury. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 102-109.	1.2	10
76	Differential Expression of the Trypsin Inhibitor SPINK3 mRNA and the Mouse Ortholog of Secretory Granule Protein ZG-16p mRNA in the Mouse Pancreas After Repetitive Injury. <i>Pancreas</i> , 2004, 28, e104-e111.	0.5	19
77	Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. <i>Hepatology</i> , 2003, 37, 1202-1219.	3.6	1,791
78	Interim results of a pilot study demonstrating the early effects of the PPAR- $\beta$ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2003, 38, 434-440.	1.8	122
79	Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR- $\beta$ ligand rosiglitazone. <i>Hepatology</i> , 2003, 38, 1008-1017.	3.6	493
80	Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. <i>Current Gastroenterology Reports</i> , 2002, 4, 31-36.	1.1	33
81	Repetitive Acute Pancreatic Injury in the Mouse Induces Procollagen $\alpha 1(I)$ Expression Colocalized to Pancreatic Stellate Cells. <i>Laboratory Investigation</i> , 2000, 80, 143-150.	1.7	79
82	Repetitive self-limited acute pancreatitis induces pancreatic fibrogenesis in the mouse. <i>Digestive Diseases and Sciences</i> , 2000, 45, 665-674.	1.1	103
83	Thiol regulation of endotoxin-induced release of tumour necrosis factor $\alpha$ from isolated rat Kupffer cells. <i>Biochemical Journal</i> , 1996, 320, 1005-1010.	1.7	66
84	The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. <i>International Journal of Gastrointestinal Cancer</i> , 1994, 16, 31-36.	0.4	5